In 2009, I wrote that while patient demand for new drugs and devices would increase, the ability of patients and healthcare organizations to pay for such new medicines would decline.  This year’s price cuts throughout Europe have now borne this out.  Drug firms from Leo Pharma to Novo Nordisk have seen wholesalers stop carrying their new drugs; the reason:  cut prices by 25% or don’t get paid … Continue reading at ComplianceZen.com →